Updates
Cures For Hair Loss 2023 - News Feed
A very good idea is to bookmark this article page in your browser or mobile browser for easy access on the latest hair loss cure and hair growth treatment news. This will allow you to check it easily for updates. If you are looking for a corresponding article from a past update, simply use the “Search” function on this site to locate the article. As always, thanks for reading and please share this information with all you feel would benefit from it!
Epibiotech Interview EPI-001 Clinical Trial In 2023
Follicle Thought published today a new interview with Epibiotech CEO Dr. Jong-Hyuk Sung. The topics covered include EPI-001 beginning its important phase 1 clinical trial in Korea, the Epibiotech pipeline, and alopecia areata therapies. Head to the Articles page, or if you are reading this long after its publication, search for "Epibiotech EPI-001 clinical trial" on this website to find the article.
Coegin Pharma To Develop Follicum’s FOL005 As Cosmetic
Coegin Pharma, the company which acquired Follicum several years ago, has new plans for the FOL005 peptide. After recently attempting to resurrect FOL005 from the clinical trials archive, the company has an even more ambitious plan for the compound - to market it as a cosmetic. This news was shared onCoegin's websitein August 2023. Apparently, discussions with industry partners helped sway Coegin's interests towards a cosmetic development route. The potential upsides are a much faster development track which would mean consumers get the treatment faster and the company generates revenue sooner. Below is a slide from Follicum's latest presentation and further below is a presentation shared in May on Follicle Thought.
Follicum sharesnew presentationwith Follicle Thought audience May 2023.
GT20029 Phase 2 China Trial Completes Male Patient Enrollment
The Kintor trial train keeps moving along. While we were once mesmerized by the thought of two AGA pipeline drugs moving to regulatory approval, expectations around pyrilutamide have likely decreased slightly, yet, hopes are still high for GT20029. In late August 2023, Kintor announced the completion of patient enrollment in its phase 2 trial for male AGA in China. This means, after the latest patients complete dosing, the trial will likely wrap up around the end of November.
Kintorofficials saytop line data is expected in Q1 2024. This will be our first look at GT20029's efficacy, which will be a meaningful and pivotal moment in the drug's development.
博士研究Verteporfin砰的一声头发移植的疤痕. Bloxham
A new documentation of a hair transplant surgeon studying the YAP inhibiting drug verteporfin in hair transplant surgery has been published on the front page. Dr. Blake Bloxham of New York has followed in the footsteps of Dr. Barghouthi in testing the application of verteporfin to the wounded scalp areas following hair transplant surgery. This work is being done to test the capacity for verteporfin to create scarless wound healing, and potentially, hair follicle regeneration in the donor extraction area.
Importantly, in the latest studies by Dr. Bloxham, verteporfin is being tested on FUT hair transplant wounds for the first time. Previously, verteporfin was only tested in microscopic FUE extraction wounds. An important update from Dr. Bloxham regarding the healing process of the FUT wounds can be expected around the end of September/early October. Follow the main article for further details.
StimuSIL Hair Growth Device Trial Listed On ClinicalTrials.Gov
Recently, you may have read about the newcomer device company, StimuSIL, on Follicle Thought. StimuSIL has created an innovation upon LLLT therapy with the hopes to create a treatment which is not only utilized, but respected, in the hair growth world. The first step in achieving that goal is to run a successful human clinical trial, which StimuSIL has embarked upon. A new listing onClinicalTrials.govreveals previously unknown details about the company's device.
New information about the StimuSIL SAGA device and trial format:
- Two device versions, SAGA-001 (A) and SAGA-001 (B) are being trialed.
- 38 adult males with androgenetic alopecia comprise the testing pool.
- Patients will receive 8 treatments over the course of 4 months (bi-weekly treatment).
- Primary outcome is the measured change in terminal hair density.
Carmell Therapeutics PRP Without Blood Draw
Earlier this week, Follicle Thought formally introduced a company developing an off the shelf version of platelet rich plasma for hair growth injections. Carmell Therapeutics is based in Pennslyvania, US and is planning to enter a large animal preclinical trial within the next several months. A clinical trial could follow shortly thereafter. Check the fullArticlefor more information.
Another Drug Approved For Alopecia Areata: Litfulo Ritlecitinib
In June 2023, the US FDA approved its second oral drug against alopecia areata, ritlecitinib. This kinase inhibitor blocks JAK 3 and tyrosine kinase which creates a therapeutic effect on auto-immune disorders. The drug will be branded as Litfulo and is intended to treat severe alopecia areata in people above the age of 12. Eli Lilly's Olumiant, which became the first approved oral drug for AA back in June 2022, isonly approvedfor adults.
Kintor KX-826 Pyrtilutamide Phase 3 Trial Approval Delayed?
2023年7月19日,Kintor制药宣布the first patient enrollment in a new long-term safety phase III trial of KX-826 in AGA in China. Note, this is in addition to the phase 3 trial for male AGA which began in January 2022 in China. The new phase 3 trial will evaluate the long-term safety and efficacy of KX-826 in males and females over the course of a 52 week dosing period and will include 270 subjects. It may be the case that the Chinese regulatory agency requested that Kintor complete a longer phase 3 trial than the original 24 week trial which began last year. At this time, it appears that the potential approval timeline for KX-826/pyrilutamide may be pushed back until the completion of the latestsafety phase 3 trial.
Mallia Therapeutics Raises Funds For CD83 Hair Growth Therapy
Head to the Articles page to read the new writeup on Mallia Therapeutics' latest developments for soluble CD83 (sCD83). Mallia Therapeutics (formerly MalliaBiotech) have also unveiled a new website which is linked in thearticle.
Life Code WCD2023 Poster
Life Code, a company participating in the World Congress of Dermatology Singapore 2023, recently shared a poster displaying hair growth data with Follicle Thought. The company uses an artificial intelligence drug discovery platform called PetaPoly to find new molecules for various biological conditions. Life Code found a molecule called LCH34 for hair growth purposes. Check the main Articles page to view Life Code's poster.